MTACU has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
MTACU has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Note: As Cyclically Adjusted FCF per Share is a main component used to calculate Cyclically Adjusted Price-to-FCF. If the month end stock price for this stock is zero, result may not be accurate due to the exchange rate between different shares and the data will not be stored into our database. Selected historical data showed in the calculation section below is only for demostration purpose.
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.
MedTech Acquisition's adjusted free cash flow per share data for the fiscal year that ended in Dec. 2022 was $0.000. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $0.00 for the trailing ten years ended in Dec. 2022.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.
As of today (2025-05-17), MedTech Acquisition's current stock price is $ 11.35. MedTech Acquisition's Cyclically Adjusted FCF per Share for the fiscal year that ended in Dec. 2022 was $0.00. MedTech Acquisition's Cyclically Adjusted Price-to-FCF of today is .
The historical data trend for MedTech Acquisition's Cyclically Adjusted FCF per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MedTech Acquisition Annual Data | |||||||
Trend | Dec20 | Dec21 | Dec22 | ||||
Cyclically Adjusted FCF per Share | - | - | - |
MedTech Acquisition Quarterly Data | ||||||||||||
Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | |
Cyclically Adjusted FCF per Share | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
- | - | - | - | - |
For the Shell Companies subindustry, MedTech Acquisition's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Diversified Financial Services industry and Financial Services sector, MedTech Acquisition's Cyclically Adjusted Price-to-FCF distribution charts can be found below:
* The bar in red indicates where MedTech Acquisition's Cyclically Adjusted Price-to-FCF falls into.
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.
What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?
Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.
If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.
We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
For example, MedTech Acquisition's adjusted Free Cash Flow per Share data for the fiscal year that ended in Dec. 2022 was:
Adj_FreeCashFlowPerShare | = | Free Cash Flow per Share | / | CPI of Dec. 2022 (Change) | * | Current CPI (Dec. 2022) |
= | / | 125.2218 | * | 125.2218 | ||
= | 0.000 |
Current CPI (Dec. 2022) = 125.2218.
MedTech Acquisition does not have a history long enough to calculate Cyclically Adjusted FCF per Share. Therefore GuruFocus does not calculate it.
MedTech Acquisition (NAS:MTACU) Cyclically Adjusted FCF per Share Explanation
If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.
For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.
Be Aware
Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.
Thank you for viewing the detailed overview of MedTech Acquisition's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Magnetar Financial Llc | 10 percent owner | 1603 ORRINGTON AVE., 13TH FLOOR, EVANSTON IL 60201 |
Magnetar Capital Partners Lp | 10 percent owner | 1603 ORRINGTON AVE., 13TH FLOOR, EVANSTON IL 60201 |
Supernova Management Llc | 10 percent owner | 1603 ORRINGTON AVENUE, 13TH FLOOR, EVANSTON IL 60201 |
David J. Snyderman | 10 percent owner | C/O MAGNETAR FINANCIAL LLC, 1603 ORRINGTON AVENUE, 13TH FLOOR, EVANSTON IL 60201 |
David L Treadwell | director | 222 S 15TH STREET, SUITE 600 N, OMAHA NE 68102 |
Manuel Aguero | director | 600 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10022 |
Thierry B. Thaure | director | 3957 POINT EDEN WAY, HAYWARD CA 94545 |
David J Matlin | director, 10 percent owner, officer: Chief Financial Officer | |
Karim Karti | director | C/O IRHYTHM TECHNOLOGIES, INC., 650 TOWNSEND STREET, SUITE 500, SAN FRANCISCO CA 94103 |
Christopher C Dewey | director, 10 percent owner, officer: Chief Executive Officer | 120 BROADWAY, 27TH FLOOR, NEW YORK NY 10271 |
Robert H. Weiss | officer: Chief Admin Officer and Sec. | 585 WEED STREET, NEW CANAAN CT 06840 |
Maurice R Ferre | director | C/O MAKO SURGICAL CORP., 2555 DAVIE ROAD, FORT LAUDERDALE FL 33317 |
Ivan Delevic | director | C/O MAKO SURGICAL CORP., 2555 DAVIE ROAD, SUITE 110, FORT LAUDERDALE FL 33317 |
Medtech Acquisition Sponsor Llc | 10 percent owner | 1345 AVENUE OF THE AMERICAS, NEW YORK NY 10105 |
Martin William Roche | director | 600 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10022 |
From GuruFocus
By GuruFocus Research • 07-28-2023
By Value_Insider Value_Insider • 12-08-2022
By Business Wire Business Wire • 06-12-2023
By Marketwired Marketwired • 12-23-2020
By GuruFocusNews GuruFocusNews • 03-10-2022
By PRNewswire PRNewswire • 08-13-2021
By PRNewswire PRNewswire • 08-19-2021
By Marketwired Marketwired • 02-06-2021
By GuruFocus Research • 08-15-2023
By PRNewswire PRNewswire • 09-09-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.